Inclusion Criteria:

          1. Male or female subjects 18 years of age or older

          2. Subjects with active acute myeloid leukemia (AML) with no available curative treatment
             options using currently available therapies. Specifically:

               1. AML that has not achieved a complete remission or morphologic leukemia free state
                  by ELN criteria (Döhner et al., 2017 Blood, 129(4):424-447); partial remission or
                  refractory disease (including primary refractory) are eligible. Or:

               2. AML relapsed following allogeneic stem cell transplantation (including MDS
                  evolved to AML post-allogeneic stem cell transplantation). Note: morphologic
                  relapse is not required; persistent/recurrent disease-associated molecular,
                  phenotypic or cytogenetic abnormalities (measurable residual disease, MRD) at any
                  time after allogeneic HCT is eligible

          3. Subjects with relapsed disease after prior transplant must meet one of the following:

             a. Subjects with relapsed disease after prior allogeneic HCT (myeloablative or
             non-myeloablative) will be eligible if they meet all other inclusion criteria and i.
             Have no residual donor cells (by STR analysis on 2 occasions separated by at least 1
             month), OR: ii. Donor cells are present but there is no active GVHD (>Gr II), subject
             does not require systemic immunosuppression and is more than 3 months from transplant,
             and at least 1 month off GVHD prophylaxis.

             b. Subjects with relapsed disease after prior autologous or syngeneic HCT will be
             eligible if they meet all other inclusion criteria and it has been more than 3 months
             from transplant.

          4. Subjects must have a suitable stem cell donor available who may donate cells in the
             event the subject needs to undergo an allogeneic HCT. Donor may be matched or
             mismatched and must be found to be suitable according to the institution's standard
             criteria; donors must be fully cleared to proceed as the donor.

          5. Satisfactory organ functions:

               1. Creatinine ≤ 1.6 mg/dl

               2. ALT/AST must be ≤5 x upper limit of normal unless related to disease

               3. Direct bilirubin or total bilirubin < 2.0mg/dl, unless subject has Gilbert's
                  syndrome (≤3.0 mg/dL);

               4. Left ventricular ejection fraction > 40% as confirmed by ECHO/MUGA

          6. ECOG Performance status 0-2.

          7. Written informed consent is given.

          8. No contraindications for leukapheresis.

          9. Subjects of reproductive potential must agree to use acceptable birth control methods
             (as described in protocol Section 4.3).

        Exclusion Criteria:

          1. Pregnant or lactating (nursing women) women.

          2. Patients with relapsed AML with t(15:17).

          3. HIV infection.

          4. Active hepatitis B or hepatitis C infection.

          5. Concurrent use of systemic steroids or immunosuppressant medications. Recent or
             current use of inhaled steroids or physiologic replacement with hydrocortisone is not
             exclusionary. For additional details regarding use of steroids while on study, please
             see Section 5.5.

          6. Any uncontrolled active medical disorder that would preclude participation as
             outlined.

          7. Subjects with signs or symptoms indicative of CNS involvement. A CNS evaluation should
             be performed as clinically appropriate to rule out CNS involvement.

          8. Known history of allergy or hypersensitivity to study product excipients (human serum
             albumin, DMSO, and Dextran 40).

          9. Class III/IV cardiovascular disability according to the New York Heart Association
             Classification (see Appendix 2).

         10. Patients with a known history or prior diagnosis of optic neuritis or other
             immunologic or inflammatory disease affecting the central nervous system, and
             unrelated to leukemia or previous leukemia treatment.

         11. Subjects with clinically apparent arrhythmia, or arrhythmias that are not stable on
             medical management, within 2 weeks of the Screening/Enrollment visit.